# Signals Article: Putative Target P15260 for Helicobacter pylori Vaccine
Background
*Helicobacter pylori* is a bacterium that infects the stomach lining and is associated with various gastrointestinal diseases, including peptic ulcers and gastric cancer. Developing an effective vaccine against *H. pylori* could significantly reduce the global disease burden associated with these conditions. Despite extensive research, no vaccine has yet reached advanced clinical trials.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P15260 was identified as a putative target for an *H. pylori* vaccine. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database. Although P15260 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, highlighting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P15260 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P15260's potential as a vaccine target. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P15260 as a vaccine target, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of *H. pylori* infection. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P15260. If validated, assessing the druggability of P15260 via DGIdb and ChEMBL will be crucial for potential therapeutic development.